Disclosures: Moony Su: Nothing to Disclose, Olivia Matthews: Resolution Therapeutics: Employee, Resolution Therapeutics: Stock privately held company, Mark Cant: Nothing to Disclose, Anna Hoy: Resolution Therapeutics: Employee, Resolution Therapeutics: Employee, Resolution Therapeutics: Stock privately held company, Niya Aleksieva: Nothing to Disclose, Rachel Lopera: Nothing to Disclose, Philip Starkey Lewis: Resolution Therapeutics Ltd: Employee, Resolution Therapeutics Ltd: Stock privately held company, Alejandro Armesilla-Diaz: Nothing to Disclose, Keith Sutton: Resolution Therapeutics: Employee, Kayleigh Thirlwell: Nothing to Disclose, Lara Campana: Resolution Therapeutics: Employee 1991 HEPATIC STELLATE CELLS FACILITATES AMMONIA DETOXIFICATION THROUGH GPT1-MEDIATED ALANINE SYNTHESIS IN HEPATOCELLULAR CARCINOMA Thi Nga Ha 1 Hyon-Seung Yi 1 Dong Wook Choi 2 , 1 Chungnam National University, 2 Korea University Background: Targeting metabolic reprogramming during the activation of hepatic stellate cells (HSCs) has recently been highlighted as an emerging strategy for mitigating hepatic diseases
You can see this enthusiasm reflected in its market growth
Qu N, Chen D, Ma B, Zhang L, Wang Q, Wang Y, et al
A profound understanding of the intersecting influences of ferroptosis and cuproptosis holds crucial clinical significance for the treatment and prevention of ischemic stroke
